Use of Anti-CD3 antibody for selectively depleting activated t cells
Monovalent anti-CD3 antibodies selectively target and eliminate activated T cells, addressing the risks of cytokine storm syndrome and inflammatory responses, thereby reducing the incidence of autoimmune diseases and graft-versus-host disease while preserving T cell levels.
Patent Information
- Application Number
- PCT/IB2024/054911
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-20
- Publication Date
- 2024-11-28
AI Technical Summary
Current antibodies used to eliminate T cells, such as anti-CD3 antibodies, can cause a cytokine storm syndrome and trigger strong inflammatory responses, leading to risks like graft-versus-host disease and organ rejection, and they often decrease T cell levels, increasing the risk of infection, necessitating a strategy to selectively remove only activated T cells to minimize these risks.
Development of monovalent anti-CD3 antibodies or their antigen-binding fragments, specifically targeting the heavy chain variable region and light chain variable region, which selectively eliminate activated T cells without affecting non-activated T cells, using forms like single-chain variable fragments (scFv) to induce apoptosis in activated T cells through the TCR/CD3 signaling pathway.
The monovalent anti-CD3 antibodies effectively reduce activated T cell populations, thereby minimizing inflammatory responses and reducing the risk of autoimmune diseases, graft-versus-host disease, and organ transplant rejection, while preserving a sufficient T cell reservoir to maintain immune function.
Smart Images

Figure IB2024054911_28112024_PF_FP_ABST
Abstract
Description
[0001]
specification
[0002]
Title of the invention
[0003]
Technical Field
[0004]
Invention Technology
[0005] T cells play a central role in antigen-specific immune responses. They are the primary cell population responsible for mediating specific immune responses to pathogen antigens when the body is invaded by pathogens, thereby protecting the body from infection. However, conversely, excessive T cell responses can induce excessive inflammatory responses in the body, mediating inflammatory diseases. For example, excessive T cell responses to self-antigens can lead to autoimmune diseases, while T cell responses to grafts during organ transplantation can result in transplant failure through graft rejection. In addition, in anti-tumor allogeneic T cell therapy, which administers another person's T cells to a patient for the purpose of treating cancer, these allogeneic donor T cells can attack the patient's normal tissues and cause graft versus host disease (GVHD), which causes inflammation. Therefore, attempts have been made to suppress T cell-mediated inflammatory responses by developing T cell-specific antibodies to remove T cells. For example, T cell-removing antibodies such as anti-CD3 antibody, anti-Thymocyte global in (ATG), and anti-CD52 antibody have been attempted, and among these, ATG and anti-CD52 antibodies are currently commercially available and in use. However, these antibodies are known to have problems such as increasing the risk of infection by causing a decrease in overall T cells, and in particular, T cell-depleting antibodies in the form of full IgG cause excessive T cell activation before T cell depletion, which can trigger a strong inflammatory response such as cytokine storm syndrome.Therefore, rather than a strategy to eliminate all T cells, it is necessary to develop a strategy to minimize the risk of cytokine storm syndrome and leave sufficient T cell reservoirs to respond to infection by temporarily eliminating only activated T cells (effector T cells) that immediately cause inflammation. Accordingly, the inventors of the present invention prepared anti-CD3 antibodies in various forms and confirmed that monovalent antibodies, especially single chain variable fragment (scFv) anti-CD3 antibodies, can selectively eliminate only activated T cells while relatively leaving non-activated T cells unaffected, thereby completing the present invention.
[0006]
Detailed Description of the Invention
[0007]
Technical Problem
[0008]
Technical Solution
[0009]
Effect of the invention
[0010]
Brief description of the drawings
[0011] [Form for carrying out the invention] Hereinafter, preferred examples are presented to help understand the present invention. However, the following examples are provided only to more easily understand the present invention, and the content of the present invention is not limited to the following examples. The examples can be modified in various ways, and the examples are not limited to the examples disclosed below, but can be implemented in various forms. Example 1. Production of activated T cells
[0012] T cells receive activation and inactivation signals through signal transmission through the T cell receptor (TCR)-CD3 complex on the cell surface. The TCR is composed of alpha and beta chains, and the CD3 complex is composed of gamma, delta, epsilon, and zeta chains. Among them, antibodies against the CD3 epsilon subunit are the best known, and when anti-CD3 epsilon antibodies (hereinafter, anti-CD3 antibodies) are added to T cells in a form coated on a solid phase (e.g., antibodies coated on a cell culture plate, also known as plate-bound antibodies), multiple antibodies simultaneously multiplex the TCR-CD3 complex (cross-linking), thereby transmitting the TCR signal into the cell. In the TCR signal, activation signals and inactivation signals ■ exist simultaneously. When antibodies against CD28, an activating receptor on the T cell surface, are added to provide a CD28 signal together, the activation signal becomes dominant, and the T cell becomes activated. Here, activated T cells were produced by stimulating normal peripheral blood T cells in vitro with plate-attached anti-CD3 and anti-CD28 antibodies. Specifically, peripheral blood mononuclear cells (PBMCs) containing a large number of T cells were isolated using the Ficoll centrifugation method, a cell separation method that utilizes the difference in cell density between cells, from normal peripheral blood cells. The isolated PBMCs were cultured with plate-attached anti-CD3 antibodies (10 ug / ml, clone 0KT3), anti-CD28 antibodies (2 ug / ml, clone CD28.2), and recombinant hIL-2 (200 U / ml, Proleukin) and activated for 5 days. During this period, only T cells survive and proliferate, so most surviving cells after 5 days are activated T cells.Afterwards, the cells were washed and cultured for an additional 3 days in a culture medium containing hIL-2 (200 U / ml) before being used as activated T cells. Experimental Example 1. Selective removal ability of monovalent anti-CD3 antibody on activated T cells.
[0013] 1.1 Selective elimination ability of 0KT3 on activated T cells Anti-human CD3 0KT3 IgG antibody was purchased commercially. To test the T cell elimination ability of monovalent soluble anti-CD3 antibody, the 0KT3 clone, which is a well-known anti-human CD3 antibody, was purified from human HEK293F cells in the form of monovalent antibody, Fab and scFv. Specifically, anti-human CD3 0KT3 Fab antibody was produced by cloning the VH-CH1 domain and VL-CL domain of each clone into an expression vector (pCEP4), and then transfecting the two plasmids into HEK293F cells. The antibody secreted into the culture medium was affinity purified (via kappa-select resin). Specifically, the anti-human CD3 0KT3 scFv antibody was cloned into pCEP4 with the scFv portion of each clone linked to Ck (kappa 1 light chain constant domain) (scFv- Ck), and this plasmid was transformed into HEK293F cells. The scFv- Ck antibody secreted into the culture medium was then affinity purified (via kappa-select resin) to produce the antibody. Tables 1 and 2 below show the sequence of the 0KT3 gene, the sequence of the Fab of 0KT3, and the sequence used to separate and purify the same, respectively.
[0014] Table 11
[0015] Table 2 Each form of purified antibody was challenged with activated human T cells at the same molar concentration (12.5 pmol antibody / 5X10 5T cells / mL) and analyzed the viability and apoptosis of T cells 24 hours later by flow cytometry. Specifically, each form of 0KT3 antibody (Fab and scFv) was added to activated T cells and cultured for 24 hours, and then T cell viability was analyzed through 7AAD staining and flow cytometry. At this time, 7AAD is a fluorescent DNA-binding compound that does not penetrate into cells when cells are alive and does not bind to the fluorescent molecule. However, when the cell membrane is destroyed as the cell dies, it enters the cell and binds to DNA, causing the cells to fluoresce. Therefore, 7AAD-negative cells are classified as live cells, and 7AAD-positive cells are classified as dead or dying cells. As shown in Figure 1, the soluble 0KT3 antibody in the form of full IgG had no effect on the viability of T cells, but the monovalent antibody forms, 0KT3-Fab and 0KT3-scFv antibodies, significantly reduced the viability of T cells (7AAD-negative cell ratio).
[0016] 1.2 Mechanism of death of activated T cells - apoptosis
[0017] In order to confirm whether the death of activated T cells by 0KT3-Fab and 0KT3-scFv antibodies in the form of monovalent antibodies was due to apoptosis, Annexin V, a marker of apoptotic cell death, and 7AAD staining were performed simultaneously, and the results are shown in Fig. 1. In early apoptotic cells, the cell membrane is stained with Annexin V, but the cell membrane has not yet been destroyed, so it takes the form of Annexin V(+) 7AAD(-), which is not stained by 7AAD. However, in late apoptotic cells, staining occurs up to 7AAD, so it takes the form of Annexin V(+) 7AAD(+). In addition, in order to further verify whether the apoptosis of activated T cells was induced by the monovalent antibody of 0KT3, the activation of caspase 3, an enzyme that mediates apoptosis, was confirmed through flow cytometry, and the results are shown in Fig. 2. As shown in Fig. 1, when each form of 0KT3 antibody was added to activated T cells and analyzed over time, the rate of early apoptosis increased rapidly from 3 hours in the groups treated with 0KT3-Fab and 0KT3-scFv antibodies, and after 6 hours, terminal apoptotic cells appeared and the rate increased rapidly thereafter. However, there was no change in the rate of apoptotic cells in the group treated with the full IgG form of 0KT3 antibody. As shown in Fig. 2, in the groups treated with 0KT3-Fab and 0KT3-scFv antibodies, activated caspase 3 (active caspase 3) was detected 3 hours after treatment, indicating that active apoptosis occurred in these cells. However, in the group treated with 0KT3 in the form of full IgG, activated caspase 3 was not detected. Through the above results, it was confirmed that 0KT3 in the form of Fab or scFv, unlike 0KT3 in the form of full IgG, induced cell death through the apoptosis pathway of activated T cells.
[0018] 1.3 Selective elimination ability of other monovalent antibodies anti-CD3 on activated T cells It was confirmed whether the T cell apoptosis-inducing ability of the monovalent 0KT3 antibody was also reproduced in other monovalent anti-CD3 antibodies. For another anti-CD3 antibody, UCHT1 antibody, a commercial IgG antibody was purchased and produced in the form of scFv using the same method as in 1.1 above, and an experiment was conducted to confirm whether it induces apoptosis of activated T cells. The sequence of UCHT1 and the sequence used to separate and purify it are shown in Table 3 below.
[0019] Table 3 In addition, to confirm the universality of apoptosis-induced cell death of anti-CD3 antibodies in the form of scFv, a novel anti-CD3 epsilon antibody was screened. Specifically, human CD3 gamma / epsilon and delta / epsilon extracellular heterodimer proteins were mixed with an adjuvant and immunized in 10 chickens four times at two-week intervals, and then the spleen, bone marrow, and synovial bursa of the chickens were collected, and total RNA was isolated, cDNA was synthesized, and variable light and heavy chain genes were PCR-PCR-performed, and a vector for phage display was used. P A chicken immune antibody library was constructed by cloning into Comb3XSS. Subsequently, bio-panning was performed to screen antibody clones that specifically bind to human CD3 protein. After separating and purifying positive antibody clones in the form of scFv, two antibodies (clones 1-4-2 and 1-4-7) that bind to CD3(+) Jurkat cell were finally selected, and an experiment was conducted to analyze whether they induce apoptosis of activated T cells using the same method as in 1.1 above. The results are shown in Fig. 3. In addition, the sequences of 1-4-2 and 1-4-7 and the sequences used for separating and purifying them are shown in Tables 4 and 5 below, respectively.
[0020] Table 4
[0021] Table 5 As shown in Figure 3, the UCHT1 antibody in the full IgG form did not affect the viability of activated T cells, whereas the scFv form of the UCHT1 antibody significantly reduced T cell viability. In addition, scFvs for two screening anti-CD3 antibody clones (1-4-2 and 1-4-7) also significantly reduced the viability of activated T cells when added to activated T cells.
[0022] 1.4 To confirm whether the apoptosis-inducing ability of monovalent anti-CD3 antibodies beyond the selective elimination ability of anti-CD3 on unactivated T cells is also observed in unactivated T cells, scFv 0KT3 antibody was added to normal peripheral blood T cells for 24 hours, and T cell death was confirmed using the same method as in Experimental Example 1.3. The results are shown in Fig. 4. As shown in Fig. 4, no apoptotic cell death was observed in unactivated T cells for any of the full IgG, Fab, or scFv 0KT3 antibodies. Through the above results, it was confirmed that the T cell killing ability of anti-CD3 antibodies is selectively eliminating against activated T cells in the form of Fab or scFv anti-CD3 antibodies, not in the form of full IgG. A total of four different monovalent anti-CD3 antibodies were confirmed to induce apoptosis in activated T cells. Experimental Example 2. Analysis of the apoptosis mechanism of monovalent anti-CD3 antibodies.
[0023] To determine whether T cell apoptosis induced by monovalent anti-CD3 antibodies is mediated by the TCR / CD3 signaling system, the TCR / CD3 signaling pathway was analyzed.
[0024] It is known that TCR / CD3 signaling of T cells activates three downstream signaling pathways: calcium-NFAT pathway, PKC0-NFKB pathway, and Erk-API pathway, following the activation of upper signaling molecules such as ZAP70-LAT-PLC x 1. Specifically, activation of the calcium-NFAT pathway can be confirmed by the rapid migration of NFAT molecules in Western blotting (NFAT is activated by dephosphorylation, and dephosphorylated NFAT is detected as a small band in SDS-PAGE), activation of the PKC0-NFKB pathway can be confirmed by the degradation of the NFkB inhibitor IkB, and activation of the Erk-API pathway can be confirmed by the detection of phosphorylated Erk (p-Erk). Accordingly, activated T cells were treated with each form of 0KT3 antibody (0KT3-IgG, OKT-Fab, 0KT3-scFv) or PMA / ionomycin (positive control), which activates all three downstream signaling pathways, and the activation of each pathway, NFATc2, IKB, P-ERK, and Total ERK, was confirmed through Western blotting, and the results are shown in Fig. 5. In addition, to verify whether the TCR / CD3 signal and its downstream NFAT pathway activation induced apoptosis by the 0KT3 antibody, the death of T cells was confirmed following the administration of a signaling inhibitor that affects the activation of the upper molecules of the TCR / CD3 signaling pathway. Specifically, activated T cells were treated with 10uM cyclosporin A (calcineurin inhibitor, CsA) in 0.01% DMSO and 100nM dasatinib (Lck inhibitor) in 0.01% DMSO along with anti-CD3 antibody, and 0.01% DMSO was used as the negative control group (Vehicle). The results are shown in Fig. 6.As shown in Figure 5, when comparing each group with the positive control group that induced activation of all three pathways, no significant activation was observed in all three pathways for OKT3-IgG, but activation of NFAT was observed in cells treated with Fab and scFv. On the other hand, activation of the NFkB and Erk-AP pathways was not observed. Therefore, it was confirmed that monovalent OKT3 antibodies activate the NFAT pathway during TCR / CD3 signaling. As shown in Figure 6, dasatinib (Dasa) significantly inhibited apoptosis induced by 0KT3-scFv, and cyclosporinA (CsA) partially inhibited apoptosis. In other words, it was confirmed that 0KT3-scFv induces apoptosis through TCR / CD3 signaling, and particularly that the NFAT pathway is involved. Experimental Example 3. Ability to eliminate residual TCR-positive CAR T cells in anti-CD3 subsets in allogeneic CAR T cell therapy.
[0025] 3.1 Incomplete TCR deletion by CRISPR / Cas9 technique and / or MACS Most anti-tumor CAR T-cell therapies are in the form of autologous CAR T-cell therapy, which extracts autologous T cells from the patient's peripheral blood, introduces CAR genes, and then returns them to the patient. In the case of autologous CAR T cells, the process of extracting T cells from the patient and manufacturing CAR T cells takes a considerable amount of time, and in some cases, CAR T-cell manufacturing may fail due to poor T-cell condition of the patient. Therefore, allogeneic CAR T-cell therapy is being attempted, in which CAR T cells are manufactured in advance from peripheral blood T cells (allogeneic T cells) collected from a healthy person, frozen, and then immediately administered to the patient in need. However, in the case of allogeneic CAR T-cell therapy, there is a possibility that the administered allogeneic CAR T cells may attack the patient's normal tissues and cause graft-versus-host disease (GVHD) side effects that cause severe inflammation. Therefore, there are attempts to prevent GVHD side effects by manufacturing CAR T cells with the TCR / CD3 complex of T cells that induce graft-versus-host disease removed using CRISPR / CAS9 gene editing technology. However, there is a problem that some residual TCR-positive CAR T cells exist due to the removal of the TCR / CD3 complex by the CRISPR / Cas9 technique.
[0026] Since TCR and CD3 are always expressed together on the cell surface in the form of a complex, if either TCR or CD3 is not expressed, the other is also not expressed. In other words, residual TCR-positive cells can be eliminated with an anti-CD3 antibody. Therefore, in the process of eliminating the TCR / CD3 complex by CRISPR / Cas9 for allogeneic CAR T-cell therapy, the monovalent anti-CD3 antibody of the present invention was used to eliminate residual TCR-positive cells. Specifically, as shown in Fig. 7, after activating T cells on day 0 of the experiment, a gRNA / Cas9 protein complex (Ribonulceoprotein: RNP) targeting TCR was constructed using a previously reported human TCR alpha chain-specific guide RNA (gRNA) sequence (GAGAATCAAAATCGGTGAAT) (Mol Ther. 2016 Mar; 24(3):570-81), and then electroporation was used to transfect T cells activated for 2 days. Afterwards, these T cells were cultured for several days in a culture medium containing hIL-2 (200U / ml), and the expression of TCR and CD3 epsilon chain on the cell surface was confirmed by flow cytometry. Residual TCR-positive T cells were confirmed by flow cytometry on days 5, 8, 11, and 14 of the experiment, and the results are shown in Fig. 7. In addition, when the existing method of MACS (magnet-associated cell sorting) purification was additionally performed to remove residual TCR-positive cells, residual TCR-positive cells were confirmed using the same method. Specifically, after removing the TCR of T cells activated for 2 days using the CRISPR / Cas9 technique, 6 days later, the T cells were treated with an anti-CD3 antibody labeled with magnetic microbeads, and then passed through a magnetic column (LD column) to trap CD3-positive cells, i.e., TCR-positive cells, in the column.TCR-negative cells that flowed through the column were harvested and further cultured in a culture medium containing hIL-2 (200 U / ml) for several days. Residual TCR-positive T cells were confirmed through flow cytometry, and the results are shown in Fig. 8. As shown in Fig. 7, it was confirmed that about 7% of TCR-positive T cells remained on the 5th day of culture, and this residual TCR positivity rate remained constant even after 2 weeks of in vitro culture. As shown in Fig. 8, even when the existing MACS (magnet-associated cell 1 sorting) purification method was used, it was confirmed that about 2% of TCR-positive T cells remained. Through the above results, it was experimentally confirmed that it is very difficult to completely eliminate TCR-positive T cells by the CRISPR / Cas9 technique using the existing MACS method.
[0027] 3.2 Residual TCR-positive T cell depletion ability of anti-CD3 scFv
[0028] After eliminating TCR-positive T cells using the CRISPR / Cas9 technique, we confirmed whether the TCR-positive T cells could be eliminated by adding the 0KT3-scFv antibody to the cell culture medium. First, as shown in Fig. 9, the 0KT3-ScFv antibody was treated on the 7th day of culture after T cell activation and anti-TCR gRNA / Cas9 complex introduction process, and the presence of residual TCR-positive T cells was confirmed after an additional 3-day culture. The results are shown in Fig. 9. As shown in Fig. 9, most of the TCR-positive T cells were eliminated, which is more effective than the conventional MACS purification method in eliminating residual TCR-positive T cells. Next, the anti-CD3 scFv of the present invention was treated to the most commonly utilized conventional anti-CD19 CAR T cells to confirm the ability to eliminate TCR-positive T cells. Specifically, the anti-CD19 CAR cDNA was produced by requesting DNA synthesis (Integrated DNA Technologies) according to the previously published sequence (US Patent Publication No. US2013 / 0287748 Al) in the form of anti-CD19 scFv, CD8 hinge and transmembrane domains, 41BB intracellular domain, and CD3 zeta intracellular domain linked together. After cloning the produced anti-CD19 CAR cDNA into a lentiviral vector, 293T cells (ATCC) were transfected with three types of packaging DNA (pMD.2G, pMDLg / pRRE, pRSV-rev) using Lipofectamin 3000 (Invitrogen). The culture supernatant containing the secreted lentivirus was harvested for 24-48 hours, filtered (0.45x1 filter) to remove cell residual particles, and concentrated 100-fold using an ultracentrifuge to be used as a lentivirus concentrate for producing CAR T cells.After activating T cells in peripheral blood mononuclear cells for 2 days, the T cells were cultured with concentrated lentivirus for 2 days to transduce the CAR gene into the T cells, thereby producing anti-CD19 CAR T cells. After that, the cells were washed to remove the virus remaining in the culture medium, and the proliferation of CAR T cells was induced by adding culture medium containing hIL-2 (200 U / ml) twice at 3-day intervals. After 7 days from the start of T cell culture, 0KT3-scFv antibody (12.5 pmol / lX10. 5 Cells) were added to the cell culture medium and cultured for 3 days, and residual TCR-positive T cells were confirmed using a flow cytometer 10 days after the start of culture. The results are shown in Fig. 10. As shown in Fig. 10, the CAR T cells with TCR removed, manufactured through TCR removal and anti-CD19 CAR gene introduction, showed the presence of more than 10% TCR-positive T cells on the 7th day of culture, but when additional culture was performed in the presence of 0KT3-ScFv for 3 days, it was confirmed that most of the residual TCR-positive CAR T cells were removed. Additionally, in order to confirm whether the tumor-killing ability and other functions of the existing CAR T cells are maintained when the anti-CD3 scFv of the present invention is treated on the conventional universal anti-CD19 CAR T cells, the target of the CAR T cells, CD19-positive Raji cell line, was cultured together to confirm the cytokine secretion ability and tumor-killing ability. Specifically, Raji-Luc cells (3X10) that overexpressed luciferase in CD19-positive Raj cells 4 ) were cultured with CAR T or T cells for 18 hours, and then the culture medium was treated with luciferin (6 mg / ml) to measure the luminescence of the surviving Raji-Luc cells using a luminometer, thereby deriving the cell survival rate, and the cell killing ability was calculated from this (Fig. 11). The specific mathematical formula is as follows.
[0029] [Mathematical Formula 1]
[0030] Viability of Raji-Luc cells (%) = [(luminescence of experimental group) - (background luminescence)] / [(luminescence when only Raji-Luc cells are present) - (background luminescence)] xlOO.
[0031] [Mathematical Formula 2] Cell killing capacity (% cytotoxicity) = 100-cell viability. In addition, cytokine secretion capacity was measured by measuring INF- x secreted when antibody-treated CAR T cells or T cells were co-cultured with CD19C+) tumor cells. Specifically, 1.5X10 5 CD19-positive Raji cell line and 3X10 4 After 24 hours of co-culturing with CAR T cells, the culture medium was obtained and tested according to the manufacturer's experimental method of the human IFN- x ELISA kit (R&D) to measure the amount of human INF- x in the culture medium (Fig. 11). As shown in Fig. 11, it was confirmed that both the tumor killing power and cytokine secretion ability of CAR T cells were maintained at a similar level to CAR T cells that were not treated with antibodies. Through the above results, it was confirmed that the possibility of alleviating or improving side effects such as graft-versus-host disease can be confirmed by treating the residual TCR-positive CAR T cells generated during the TCR removal process of allogeneic CAR T cells with a monovalent anti-CD3 antibody to effectively remove the residual TCR-positive CAR T cells.
[0032] 3.3 Effect of preventing graft-versus-host disease by removing residual TCR-positive CAR T cells by anti-CD3 scFv (in vivo) In order to confirm whether graft-versus-host disease caused by residual TCR-positive CAR T cells generated during the process of producing allogeneic CAR T cells can be prevented by treating with the monovalent anti-CD3 antibody (0KT3 scFv) of the present invention, an in vivo experiment was performed. Although it is difficult to directly implement graft-versus-host disease caused by allogeneic CAR T cells in mice, when human CAR T cells are administered to immunodeficient mice, the TCR of the human CAR T cells recognizes the MHC molecules of mouse normal cells and induces attacks on mouse tissues, thereby simulating allogeneic GVHD caused by the donor's allogeneic CAR T cells attacking the recipient's MHC. This is called xenogeneic graft-versus-host disease (GVHD). That is, when human CAR T cells expressing TCR are administered to immunodeficient mice inoculated with human tumors, the tumor eradication effect by CAR T cells can be observed in vivo in the mice for the first month, but after that, xenogeneic graft-versus-host disease side effects in which human CAR T cells attack mouse normal tissues can be observed. Specifically, after 2.5 Gy total body radiation irradiation of immunodeficient NSG mice, CD19-positive Raj i-Luc cell line 5xl0 5 Cells were injected intravenously. Three days after Rajgup cell injection, 5xl0 per mouse were injected with anti-CD19 CAR T cells produced from human T cells, anti-CD19 CAR T cells with TCR removed, or anti-CD19 CAR T cells with residual TCR positive cells removed by treating with 0KT3-scFv antibody. 6Each mouse was injected intravenously. After tumor cell injection, the bioluminescence of the tumor was measured using an in vivo imaging system (IVIS) at one-week intervals, and each mouse was injected intraperitoneally with 2 mg of luciferin dissolved in 100 μl of saline, and images of the tumor in the body were obtained through IVIS 10 minutes later, which are shown in Fig. 12. As shown in Fig. 12, the tumor proliferation in the mouse was measured over time using bioluminescence imaging. All individuals in the group that was administered only the tumor died within 2-3 weeks, whereas the group that received the three CAR-T cells showed almost no tumor proliferation, and all individuals survived for up to 3 weeks, showing excellent therapeutic efficacy, confirming that the antitumor efficacy of the CAR T cells was well maintained. However, 10 weeks after tumor administration, all mice in the three CAR T cell administration groups died of graft-versus-host disease: mice administered the existing anti-CD19 CAR T cells, mice administered the anti-CD19 CAR T cells in which the TCR was removed but residual TCR-positive cells remained, and mice administered the anti-CD19 CAR T cells in which residual TCR-positive cells were removed by treatment with the 0KT3-scFv antibody survived without the side effects of graft-versus-host disease (Fig. 13). In addition, the incidence of graft-versus-host disease was compared in mice administered the anti-CD19 CAR T cells manufactured with each human T cell, the anti-CD19 CAR T cells in which the TCR was removed but residual TCR-positive cells remained, or the anti-CD19 CAR T cells in which residual TCR-positive cells were removed by treatment with the 0KT3-scFv antibody. The incidence of graft-versus-host disease was measured by body weight and graft-versus-host disease score (GVHD score).Each body weight and graft-versus-host disease score were measured twice a week, and the graft-versus-host disease score was calculated by adding up scores from 0 to 3 based on five clinical symptoms (skin, hair condition, posture, activity, and inflammatory eye disease). Each was measured up to 80 days after tumor administration, and the results are shown in Fig. 13. As shown in Fig. 13, in the case of the general CAR T cell administration group without a deleted TCR (Conv CAR-T), body weight decreased from 2 weeks after tumor administration, clinical findings of graft-versus-host disease were shown, and all individuals died of graft-versus-host disease after 3 weeks. In the CAR T cell administration group (De l CAR-T) where the TCR was removed but residual TCR-positive cells remained, weight loss and the severity of graft-versus-host disease were somewhat reduced compared to the Conv CAR-T cell group, but the mice still died of graft-versus-host disease at 8-9 weeks. This indicates that the residual TCR-positive CAR T cells caused severe graft-versus-host disease side effects. On the other hand, in the CAR T cell administration group (De l Ab CAR-T) where residual TCR-positive cells were completely removed by treatment with anti-CD3 scFv antibody, all animals survived long-term without weight loss or signs of graft-versus-host disease, demonstrating anti-tumor efficacy without side effects. Through the above results, it was confirmed that efficient and complete removal of residual TCR-positive cells through treatment with monovalent anti-CD3 antibody during the manufacturing process of allogeneic CAR T cells can significantly reduce the side effects of graft-versus-host disease of allogeneic CAR T cells. Experimental Example 4. Effect of Selective Elimination of Peripheral Blood Activated T Cell Population by Anti-CD3 Antibody Through the above experimental example, it was confirmed that the monovalent anti-CD3 antibody of the present invention can prevent or treat the side effects of graft-versus-host disease by eliminating residual TCR-positive cells during the process of manufacturing allogeneic CAR T cells.In addition, the monovalent anti-CD3 antibody of the present invention has the potential to be used as a therapeutic agent by directly eliminating activated T cells in the patient's body when directly administered to a patient suffering from an inflammatory disease caused by activated T cells. Examples of such diseases include autoimmune diseases, graft-versus-host disease, or organ transplant rejection. That is, if the monovalent anti-CD3 antibody can selectively eliminate activated T cells that mediate inflammation when administered to a patient showing an autoimmune disease, graft-versus-host disease, or organ transplant rejection, it can be utilized as an immunosuppressant by suppressing the inflammatory response caused by T cells while minimizing the risk of infection by preserving naive T cells or memory T cells. Therefore, the present invention was designed to confirm whether the activated T cell population among blood cells in the human body can be selectively eliminated by treating with the anti-CD3 scFv antibody (0KT3-ScFv) of the present invention. Specifically, the peripheral blood mononuclear cell (PBMC) T cell population collected from a normal person was classified into subpopulations according to their activation history using CD45RA and CCR7 expression as markers. The CD45RA(+)CCR7(+) group is mostly composed of naive T cells that have never been activated, with some stem cell memory T cells in the resting phase mixed in (N / SCM), and the CD45RM-)CCR7(+) group is a central memory T cell population (CM) that has been activated but is in the resting phase. All of these cell populations are currently in the resting phase and inactive cell populations. On the other hand, the CCR7(-) cell population is composed of activated effector T cells or effector memory T cells that can be activated immediately (EF / EM). Therefore, the EF / EM cell population includes many currently activated T cells.Here, after culturing normal peripheral blood mononuclear cells with 0KT3-scFv antibody for 3 days, the proportion of inactivated and activated T cell subpopulations and the decrease in cell number were analyzed through flow cytometry analysis of T cell subpopulations within peripheral blood mononuclear cells. More specifically, cell counting beads (Thermo Scientific) were added during flow cytometry analysis, and the number of cells passing through the flow cytometer per unit volume was measured to calculate the number of T cells and each subpopulation. After staining with anti-CD3-PE, anti-CD4-APC-Cy7, anti-CD8-PE-Cy7, ant i-CD45RA-FITC, ant i -CCR7-APC, and 7-AAD, the 7-AAD-negative, CD3-positive cell population was gated, and the fraction of each subpopulation of T cells in CD4-positive cells and CD8-positive cells was analyzed. The results are shown in Figs. 14 to 16. As shown in Figs. 14 to 16, the total number of T cells decreased by approximately 30% after 3 days of 0KT3-scFv antibody treatment (Fig. 14). Among these, the ratio of EF / EM group (activated T cells) compared to N / SCM and CM groups (inactivated T cells) was partially reduced in both CD4 and CD8 T cells (Figs. 15 and 16). In addition, as a result of calculating the absolute number of cells in each subpopulation, in CD4 T cells, there was some decrease in the number of cells in the N / SCM group and CM group (inactivated T cells) due to antibody treatment, but the decrease in the number of cells in the EF / EM (activated T cells) group was much more prominent. In CD8 T cells, there was no change in the number of cells in the N / SCM group and CM group (inactivated T cells) due to antibody treatment, whereas a clear decrease in the number of cells in the EF / EM group (activated T cells) was observed.Furthermore, even when calculated as the cell number reduction rate in the antibody-treated group compared to the non-antibody-treated group, it was confirmed that the relative cell number reduction rate of the EF / EM group (activated T cells) was significantly higher in both CD4 and CD8 T cells (Figure 16). Through the above results, it was confirmed that the monovalent anti-CD3 antibody has a selective elimination effect on the activated cell group among peripheral blood T cells and can be usefully used as a multi-purpose selective activated T cell eliminator and T cell immunosuppressant. Experimental Example 5. In vivo activated T cell elimination by anti-CD3 antibody To confirm whether the activated T cell elimination effect is observed even when the monovalent anti-CD3 antibody is directly administered in vivo ( / 刀 r / w), human T cells activated in vitro were administered to immunodeficient mice, and then the monovalent anti-CD3 antibody (UCHT1-scFv) was intravenously administered several times at intervals of two days, and the death of human T cells was traced and observed. At this time, by using human T cells artificially expressing the luciferase enzyme, the in vivo bioluminescence of human T cells could be traced using an in-vivo imaging system (IVIS). Specifically, for the production of luciferase-expressing human T cells, the high-sensitivity luciferase (eff-Luc) cDNA obtained from pD0NR222-eGFP (Addgene plasmid #364493) was cloned into a partially modified pCDH-EF1 vector (Addgene Plasmid #72266) so as to be expressed together with the GFP cDNA. The cloned lentiviral plasmid was transfected into the 293T cel 1 1 ine (ATCC) together with three types of packaging DNA (pMD.2G, pMDLg / pRRE, pRSV—rev) using Lipofectamine 3000 (Invitrogen), and then the culture supernatant containing the lentivirus secreted for 24 and 48 hours was harvested and 0.After removing residual cell particles using a 45x1 filter and concentrating 100-fold using an ultracentrifuge, the cells were used as a lentivirus concentrate for transduction. White blood cells obtained through blood collection (leukapheresis) from normal individuals were added together with anti-CD28 antibody (CD28.2, 2 / / g / mt, BD Biosciences) to a 24-well plate coated with anti-CD3 antibody (0KT3, 10w / mt, BioXcell) and cultured for 48 hours to activate T cells. Afterwards, the lentivirus concentrate for luciferase expression was mixed with the T cell culture medium and cultured together. Two days after transduction using lentivirus, the cells were washed to remove any remaining viruses in the culture medium, and cultured by adding a culture medium containing human IL-2 (200U / mt) twice every three days (day 3 + day 3) (10-day protocol). In the case of luciferase-expressing T cells, the presence or absence of T cells and the degree of proliferation can be confirmed in vivo through IVIS, so 5xl0 luciferase-expressing human T cells were injected into immunodeficient NSG mice. 6Cells were injected intravenously. After human T cell injection, the distribution of luciferase-expressing T cells in vivo was confirmed using an in vivo imaging system at one-week intervals. 14 days after T cell injection (at which point T cells were observed in all mice through IVIS), monovalent anti-CD3 antibody (UCHT1-scFv, low dose: 20 ug / ea, high dose: 100 ug / ea) diluted in 200 ul of PBS was intravenously injected once every other day for a total of five times. From the time of injecting monovalent anti-CD3 antibody, the distribution of T cells in the mice was confirmed using IVIS once every other day. Each mouse was injected intraperitoneally with 2 mg of luciferin dissolved in 100 ul of saline. The size of tumor cells was measured using IVIS 10 minutes after intraperitoneal injection. The experimental results are shown in Figs. 17 and 18, and it was found that in the group administered monovalent anti-CD3 antibody, in vivo T cells were significantly eliminated, and the greater the amount of monovalent anti-CD3 antibody administered, the faster and more clearly in vivo T cells were reduced, and it was confirmed that it was dose-dependent. Experimental Example 6. Inhibition of T-cell-mediated disease in vivo by anti-CD3 antibody When luciferase-expressing human T cells are injected into the immunodeficient mouse, xenogeneic graft-versus-host disease (GVHD) is induced, in which human T cells attack normal mouse tissues and cause inflammation. Therefore, it was tested whether xenogeneic GVHD can be inhibited by the elimination of human T cells when monovalent anti-CD3 antibody is administered. The severity of graft-versus-host disease in mice was measured in two ways (body weight, graft-versus-host disease score [GVHD score]). Weight and graft-versus-host disease scores were measured twice a week, and the graft-versus-host disease score was scored from 0 to 3 points based on five disease scales (skin, hair condition, posture, activity, and inflammatory eye disease) and then totaled.Figure 19 shows the results of evaluating body weight loss, clinical symptoms of graft-versus-host disease, and mortality rate when monovalent anti-CD3 antibody (UCHT1-scFv) was administered after xenograft graft-versus-host disease was induced by human T cells in an immunodeficient mouse model. From Figure 19, it was confirmed that when monovalent anti-CD3 antibody was treated, body weight loss, clinical symptoms, and mortality rate due to graft-versus-host disease were all significantly reduced. Therefore, since monovalent anti-CD3 antibody can significantly suppress inflammatory diseases induced by T cells, it is highly likely that it will be developed as a treatment for autoimmune diseases, which are similar T cell-mediated inflammatory diseases. In addition, it may also be used for the treatment of allogeneic graft-versus-host disease (allogeneic GVHD) caused by donor T cells after allogeneic hematopoietic stem cell transplantation (allogeneic hematopoietic stem cell transplantation) for the treatment of hematological malignancies, which is a disease similar to graft-versus-host disease of the above model.
[0033] To determine whether monovalent anti-CD3 antibodies have the potential to suppress recipient T-cell-mediated organ rejection after organ transplantation, we administered activated human T cells to an allogeneic mouse skin transplantation model in which skin from an allogeneic strain of C57BL6 mice was transplanted into immunodeficient NSG mice. This was followed by a test to determine whether graft rejection, which inhibits the engraftment of the transplanted skin, occurred. Specifically, tail skin (lxlx0.5cm3) derived from female C57BL / 6 mice was transplanted onto the tail of female immunodeficient NSG mice. Tail skin used for transplantation was stored in a PBS solution for up to 30 minutes before use. NSG mice were anesthetized with Avertin (8-10mg / PBS 400ul, intraperitoneal injection) throughout the surgical procedure. Three pieces of donor skin were grafted onto each tail of one NSG mouse. The grafted area was secured with a glass tube and an adhesive bandage for 3 days to protect the grafted skin. Graft survival was visually assessed daily. Graft rejection was defined as necrosis of 75% of the grafted skin surface. Fourteen days after tail skin grafting, 2x106 activated human T cells were injected intravenously. Monovalent anti-CD3 antibody (UCHT1-scFv, 100 ug / ea, intraperitoneal injection) diluted in 200 µl of PBS was injected once every other day, starting on the day of T cell administration, for a total of four injections. After a 6-day rest, a second injection was administered in the same manner as the first injection, for a total of eight monovalent anti-CD3 antibody injections.Graft engraftment was measured using the formula '[number of grafted skin remaining as of the observation date] / [number of grafted skin remaining on the day of T cell injection (14 days after skin grafting)]*100'. Figure 20 shows the results of observing whether a graft rejection reaction in which skin tissue is shed by human T cells occurs when monovalent anti-CD3 antibody (UCHT1-scFv) is administered in an immunodeficient mouse model. As shown in Figure 20, in the group administered only human T cells, a graft rejection reaction in which most of the grafted skin tissue was shed was observed, but in the group administered monovalent anti-CD3 antibody together, the engraftment rate of the grafted skin was confirmed to be significantly improved. Therefore, monovalent anti-CD3 antibody will be useful as an immune rejection suppressor in organ transplantation. The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive.
Claims
【Scope of Claims】 【 Claim 11 A pharmaceutical composition for preventing or treating T cell-mediated autoimmune diseases, graft-versus-host diseases or organ transplant rejection, comprising a monovalent antibody or an antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region of an antibody that specifically binds to CD3. 【
2. A pharmaceutical composition according to claim 1, wherein the antigen-binding fragment is Fab, Fab', Fv, scFv or a single-domain antibody (sdAB). 【
3. In claim 1, the antibody specifically binding to CD3 is 0KT3, UCHT1, Teplizumab, Otelixizumab, Visi lizumab, Foralumab; an antibody comprising a light chain variable region comprising LCDR1 of SEQ ID NO: 23, LCDR2 of SEQ ID NO: 24, and LCDR3 of SEQ ID NO: 25, and a heavy chain variable region comprising HCDR1 of SEQ ID NO: 26, HCDR2 of SEQ ID NO: 27, and HCDR3 of SEQ ID NO: 28; A pharmaceutical composition, wherein the pharmaceutical composition is one selected from an antibody comprising a light chain variable region comprising LCDR1 of SEQ ID NO: 32, LCDR2 of SEQ ID NO: 33, and LCDR3 of SEQ ID NO: 34, and a heavy chain variable region comprising HCDR1 of SEQ ID NO: 35, HCDR2 of SEQ ID NO: 36, and HCDR3 of SEQ ID NO:
37. 【
4. In claim 1, the antibody specifically binding to CD3 is tecl istamab, tebentafusp, blinatumomab, catumaxomab, TNB-486, AMG562, duvortuxizumab, AMG910, pasotuxizumab, HPN424, AMG 160, JNJ-63898081, CC-1, AMG 509, HPN536, odronextamab, epcoritamab, glofitamab, mosunetuzumab, JNJ-75348780, Vixt imotamab, AMG 330, REGN4018, AMG199, MGD007, EGFR BAT, AMG596, M701, solitomab, MT110, AMG110, AMG 211, MED I -565, cibisatamab, tidutamab, talquetamab, RG6194, GBR 1302, M802, Runimotamab, GEN1044, GEN1047, PF-07062119, AMG 757, BI 764532, HPN328, Hu3F8— BsAb, A pharmaceutical composition comprising a CD3 binding antibody selected from GEM3PSCA, IMC-C103C, IMC-F106C, JNJ-70218902, AMG 424, Elranatamab, ABBV-383, AMG 420, CC-93269, Linvose Itamab, Alnuctamab, Cevostamab and AMG 427, wherein the heavy chain variable region and the light chain variable region target CD3.
5. A pharmaceutical composition according to claim 1, wherein the monovalent antibody or antigen-binding fragment thereof induces death of activated T cells and / or suppresses an alloreactive immune response. 【
6. In claim 1, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, Crohn's disease, scleroderma, Sjogren's syndrome, psoriasis, inflammatory bowel disease, ulcerative colitis, ankylosing spondylitis, interstitial lung disease, uveitis, optic neuritis, peripheral neuropathies, and synovitis. A pharmaceutical composition selected from the group consisting of (sarcoidosis), antiphospholipid syndrome, inflammatory myopathies, Behcet's disease, alopecia areata / universalis, pemphigus vulgaris, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Guillain-Barré syndrome, celiac disease, and pernicious anemia. 【
7. A pharmaceutical composition according to claim 1, used in combination with an immunosuppressant.
8. A pharmaceutical composition for suppressing T cell immunity or eliminating activated T cells, comprising a monovalent antibody or an antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region of an antibody that specifically binds to CD3. 【Claims A method for suppressing T cell immunity, comprising administering a monovalent antibody or an antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region of an antibody that specifically binds to CD3.
10. (a) a step of down-regulating the expression of T cell receptor (TCR) in T cells; (b) a step of introducing a chimeric antigen receptor (CAR) into T cells, and (c) A method for removing TCR (T cell receptor) positive CAR-T cells, comprising a step of treating cells obtained in steps (a) and (b) with a monovalent antibody or an antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region of an antibody that specifically binds to CD3, wherein steps (a) and (b) are performed regardless of the order.
11. A method according to claim 10, wherein the step of down-regulating the expression of TCR is performed by a genome editing technique, siRNA, shRNA or miRNA.
12. The method of claim 11, wherein the genome editing technique is performed by CRISPR (clustered regularly interspaced short palindromic repeats) / Cas 9, TALEN, zinc finger nuclease, base editing, or prime editing.
13. An antibody or antigen-binding fragment thereof, comprising a light chain variable region comprising LCDR1 of SEQ ID NO: 23, LCDR2 of SEQ ID NO: 24, and LCDR3 of SEQ ID NO: 25, and a heavy chain variable region comprising HCDR1 of SEQ ID NO: 26, HCDR2 of SEQ ID NO: 27, and HCDR3 of SEQ ID NO: 28, or a light chain variable region comprising LCDR1 of SEQ ID NO: 32, LCDR2 of SEQ ID NO: 33, and LCDR3 of SEQ ID NO: 34, and a heavy chain variable region comprising HCDR1 of SEQ ID NO: 35, HCDR2 of SEQ ID NO: 36, and HCDR3 of SEQ ID NO:
37.
14. An antibody or antigen-binding fragment thereof according to claim 13, comprising a light chain variable region comprising an amino acid sequence of SEQ ID NO: 29 or 38 and / or a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 30 or 39.
15. A polynucleotide encoding the antibody of claim 13 or an antigen-binding fragment thereof.
16. An expression vector comprising the solinucleotide of claim 15.
17. A cell comprising the polynucleotide of claim 15 or an expression vector comprising the same.
Citation Information
Patent Citations
Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer
US20130287748A1
Process for the purification of recombinant polypeptides
WO1988007085A1
Leader sequences for the production of recombinant proteins
WO1988007086A1
Targeted multifunctional proteins
WO1988009344A1
Antibody and Methods for Selective Inhibition of T-Cell Responses
KR1020140091038A
